What was the median overall survival in ETER701?

Reconstructed medians (Months): Benmelstobart + anlotinib + EC 19.3; Anlotinib + EC 13.1; EC alone 12.0. See the published article for the official values.

What was the hazard ratio for overall survival in ETER701?

The figure reports a hazard ratio of 0.61 (95% CI 0.47–0.79) for Benmelstobart + anlotinib + EC vs EC alone. TrialCurve's reconstruction gives 0.608.

What was the median progression-free survival (pfs) in ETER701?

Reconstructed medians (Months): Benmelstobart + anlotinib + EC 6.9; Anlotinib + EC 5.7; EC alone 4.2. See the published article for the official values.

What was the hazard ratio for progression-free survival (pfs) in ETER701?

The figure reports a hazard ratio of 0.32 (95% CI 0.26–0.41) for Benmelstobart + anlotinib + EC vs EC alone. TrialCurve's reconstruction gives 0.338.

Home / Trials

ETER701: reconstructed Kaplan–Meier curves

Name: ETER701 Progression-free survival (PFS): reconstructed pseudo-IPD
Creator: TrialCurve
License: https://creativecommons.org/licenses/by/4.0/

Updated 2026-09-25 · reconstructed by TrialCurve from a CC BY-licensed publication

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.

Publication	Nat Med. 2024 Jul 11;30(10):2967–76. doi: 10.1038/s41591-024-03132-1
DOI	10.1038/s41591-024-03132-1
Registry	NCT04234607
Phase	Phase 3
Conditions	Extensive Small Cell Lung Cancer
Interventions	TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)
Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Enrolment	738
Source licence	Figure published under CC BY 4.0

Overall survival — ITT population

From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: Benmelstobart + anlotinib + EC 19.3 months; Anlotinib + EC 13.1 months; EC alone 12.0 months. Survival at 12 months: Benmelstobart + anlotinib + EC 64%; Anlotinib + EC 53%; EC alone 50%. Hazard ratio Benmelstobart + anlotinib + EC vs EC alone 0.61 (95% CI 0.47–0.79).

Arm	N	Events	Median (Months)
Benmelstobart + anlotinib + EC	246	95	19.3
Anlotinib + EC	245	123	13.1
EC alone	247	134	12.0

Benmelstobart + anlotinib + EC vs EC alone: reconstructed HR 0.61 (95% CI 0.47–0.79)
Anlotinib + EC vs EC alone: reconstructed HR 0.85 (95% CI 0.67–1.09)

Landmark survival (reconstructed)

Time	Benmelstobart + anlotinib + EC	Anlotinib + EC	EC alone
6 mo	89.0%	89.3%	85.3%
12 mo	63.9%	53.3%	49.7%
18 mo	50.4%	34.8%	26.0%
24 mo	41.8%	22.9%	24.2%

Checks against the published figure

Benmelstobart + anlotinib + EC median: printed 19.3, reconstructed 19.3 pass
Anlotinib + EC median: printed 13.3, reconstructed 13.1 pass
EC alone median: printed 11.9, reconstructed 12 pass
Benmelstobart + anlotinib + EC events: printed 95, reconstructed 95 pass
Benmelstobart + anlotinib + EC n: printed 246, reconstructed 246 pass
Anlotinib + EC events: printed 123, reconstructed 123 pass
Anlotinib + EC n: printed 245, reconstructed 245 pass
EC alone events: printed 134, reconstructed 134 pass
EC alone n: printed 247, reconstructed 247 pass
hazard ratio: printed 0.61, reconstructed 0.608 pass
hazard ratio: printed 0.86, reconstructed 0.854 pass

Download pseudo-IPD (CSV)

Progression-free survival (PFS) — ITT population

From figure panel a · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: Benmelstobart + anlotinib + EC 6.9 months; Anlotinib + EC 5.7 months; EC alone 4.2 months. Survival at 6 months: Benmelstobart + anlotinib + EC 59%; Anlotinib + EC 49%; EC alone 16%. Hazard ratio Benmelstobart + anlotinib + EC vs EC alone 0.34 (95% CI 0.27–0.42).

Arm	N	Events	Median (Months)
Benmelstobart + anlotinib + EC	246	144	6.9
Anlotinib + EC	245	169	5.7
EC alone	247	203	4.2

Benmelstobart + anlotinib + EC vs EC alone: reconstructed HR 0.34 (95% CI 0.27–0.42)
Anlotinib + EC vs EC alone: reconstructed HR 0.46 (95% CI 0.37–0.57)

Landmark survival (reconstructed)

Time	Benmelstobart + anlotinib + EC	Anlotinib + EC	EC alone
6 mo	58.8%	48.7%	15.9%
12 mo	27.6%	12.6%	2.1%
18 mo	21.4%	4.7%	2.1%

Checks against the published figure

Benmelstobart + anlotinib + EC median: printed 6.9, reconstructed 6.88 pass
Anlotinib + EC median: printed 5.6, reconstructed 5.66 pass
EC alone median: printed 4.2, reconstructed 4.23 pass
Benmelstobart + anlotinib + EC events: printed 146, reconstructed 144 pass
Benmelstobart + anlotinib + EC n: printed 246, reconstructed 246 pass
Anlotinib + EC events: printed 170, reconstructed 169 pass
Anlotinib + EC n: printed 245, reconstructed 245 pass
EC alone events: printed 199, reconstructed 203 pass
EC alone n: printed 247, reconstructed 247 pass
hazard ratio: printed 0.32, reconstructed 0.338 pass
hazard ratio: printed 0.44, reconstructed 0.461 pass

Download pseudo-IPD (CSV)

About these data

Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.

Related trials

Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)

Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.

Reconstruct a figure Browse all trials